title: A novel pyridazinone derivative as a nonprostanoid PGI2 agonist.
abstract: A novel optically pure pyridazinone derivative was synthesized and identified as a nonprostanoid PGI2 agonist. It inhibited ADP-induced aggregation of human platelets with an IC50 value of 0.081 microM and has high oral bioavailability (56%) with a long half-life (4.3 h) in rats.
authors.affiliation: Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Co., Ltd, Osaka, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Tsubaki
authors.forename: K
authors.initials: K
authors.lastname: Taniguchi
authors.forename: S
authors.initials: S
authors.lastname: Tabuchi
authors.forename: O
authors.initials: O
authors.lastname: Okitsu
authors.forename: K
authors.initials: K
authors.lastname: Hattori
authors.forename: J
authors.initials: J
authors.lastname: Seki
authors.forename: K
authors.initials: K
authors.lastname: Sakane
authors.forename: H
authors.initials: H
authors.lastname: Tanaka
mesh_terms: D000085:Acetates / Q000138:chemical synthesis / Q000493:pharmacokinetics*; D000244:Adenosine Diphosphate / Q000494:pharmacology; D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D011464:Epoprostenol / Q000819:agonists*; D005260:Female; D006207:Half-Life; D006801:Humans; D020128:Inhibitory Concentration 50; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000819:agonists / Q000138:chemical synthesis* / Q000493:pharmacokinetics; D011724:Pyridazines / Q000138:chemical synthesis / Q000493:pharmacokinetics* / Q000494:pharmacology*; D051381:Rats; D013329:Structure-Activity Relationship
chemical_list: D000085:Acetates; C424129:FR 181877; D010975:Platelet Aggregation Inhibitors; D011724:Pyridazines; D000244:Adenosine Diphosphate; D011464:Epoprostenol